



Title: N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in pre-clinical models of NMDA hypofunction and cognitive enhancement

Authors: K.J. Gregory\*, E.J. Herman\*, A.J. Ramsey, A.S. Hammond, N.E. Byun, S.R. Stauffer, J.T. Manka, S. Jadhav, T.M. Bridges, C.D. Weaver, C.M. Niswender, T. Steckler, W.H. Dringenburg, A. Ahnaou, H. Lavreysen, G.J. Macdonald, J.M. Bartolomé, C. Mackie, B.J. Hrupka, M.G. Caron, T. Daigle, C.W. Lindsley, P.J. Conn, C.K. Jones

Journal: J. Pharmacol. Exp. Ther.



**Supplementary Figure 3 Selectivity of N-aryl piperazines PAMs across various ion channels and GPCRs**

Radioligand-based binding assays were performed across 68 different targets in the presence of 10  $\mu$ M DPFE (grey bars) or VU0364289 (black bars) using Panlabs LeadProfilingScreen (Ricerca Biosciences, Concord, OH). Data represent mean of 2 independent determinations. Greater than 50% inhibition of binding (denoted by the dashed line) is considered significant.